Chronic Hepatitis B: Tenofovir, Entecavir, and Functional Cure Strategies
Sam Anderson
Treatment Indications: Who Needs Antiviral Therapy
Chronic hepatitis B management requires long-term thinking. Unlike hepatitis C, which can be cured with a short course of direct-acting antivirals, HBV treatment is typically suppressive rather than curative, and the decision to initiate antiviral therapy involves weighing the phase of infection, degree of liver inflammation and fibrosis, and the patient's willingness to commit to indefinite treatment. For the gastroenterologist, hepatologist, or infectious disease specialist, understanding treatment indications, the choice between tenofovir and entecavir, and the emerging functional cure strategies is essential for optimizing long-term outcomes.
The 2022 AASLD guidance and 2024 EASL Clinical Practice Guidelines recommend antiviral therapy for all patients with HBV DNA above 2,000 IU/mL and ALT above the ULN (35 U/L for males, 25 U/L for females per AASLD-defined thresholds), significant fibrosis (Metavir F2 or above), cirrhosis regardless of HBV DNA level, and immunosuppressed patients with any detectable HBV DNA. The simplified AASLD 2023 algorithm expands treatment eligibility to include all HBeAg-positive patients over age 30 with HBV DNA above 10,000 IU/mL regardless of ALT, reducing the number of patients in the monitoring-only category.
Tenofovir versus Entecavir: Comparative Efficacy
Both tenofovir disoproxil fumarate (TDF, 300 mg daily) and entecavir (ETV, 0.5 mg daily for treatment-naive) achieve HBV DNA suppression below 20 IU/mL in 93-97% of patients by 48 weeks[1]. A landmark Korean cohort study (Choi et al., 2019, JAMA Oncology) suggested TDF may reduce HCC risk compared to ETV (adjusted HR 0.68, 95% CI 0.59-0.78)[1], though subsequent randomized trials (including the 2024 TARGET study) found no significant difference in HCC incidence (HR 0.92, 95% CI 0.65-1.31). Tenofovir alafenamide (TAF, 25 mg daily) provides comparable virologic efficacy with significantly less renal and bone toxicity: at 96 weeks, the TAF pivotal trials showed 0% versus 5% decline in hip BMD and 0.1% versus 1.2% decline in eGFR compared to TDF[1].
Monitoring on Antiviral Therapy
HBV DNA quantification every 3-6 months until undetectable, then every 6-12 months. HBeAg and anti-HBe every 6-12 months for HBeAg-positive patients. HBsAg quantification annually guides functional cure trajectory: an annual decline exceeding 0.5 log IU/mL predicts eventual HBsAg loss. ALT and hepatic function panels every 6 months. For patients on TDF, serum creatinine, phosphate, and urinalysis annually to monitor for renal and bone effects. HCC surveillance with abdominal ultrasound plus AFP every 6 months for patients with cirrhosis, significant fibrosis, or additional risk factors (Asian males above 40, Asian females above 50, family history of HCC, or African-origin patients above 20). Co-infection with hepatitis C should also be screened for and treated.
Functional Cure: HBsAg Loss Strategies
Functional cure, defined as sustained HBsAg loss with or without anti-HBs seroconversion, occurs in less than 1% per year with nucleos(t)ide analogs alone. Peginterferon alfa-2a (180 mcg weekly for 48 weeks) achieves HBsAg loss in 3-7% of HBeAg-positive patients at 1 year post-treatment[1]. The combination of NUC plus peginterferon (add-on or switch strategies) increases HBsAg loss rates to 8-12% in selected patients with declining HBsAg levels below 1,000 IU/mL. Novel agents in phase 2-3 trials include RNA interference (bepirovirsen showed 9% HBsAg loss at 24 weeks in the B-Clear study[3]), core protein allosteric modulators, and therapeutic vaccines targeting cccDNA and integrated HBV DNA.
Safe Discontinuation of Antiviral Therapy
NUC discontinuation can be considered in non-cirrhotic HBeAg-negative patients with sustained virologic suppression (HBV DNA undetectable for 3 or more years) and HBsAg levels below 100 IU/mL. The STOP-NUC trial demonstrated HBsAg loss at 144 weeks in 19% of patients who discontinued TDF versus 3% who continued (p<0.001), though 48% experienced hepatitis flares[2]. The RETRACT-B study confirmed that low baseline HBsAg (below 100 IU/mL) is the strongest predictor of successful discontinuation. Close monitoring with ALT and HBV DNA every 4 weeks for 3 months, then every 3 months for 1 year, is mandatory after discontinuation.
The HCC Surveillance Imperative
Every patient with chronic hepatitis B — regardless of whether they are on antiviral therapy and regardless of viral suppression status — requires hepatocellular carcinoma surveillance if they meet risk criteria. This includes all patients with cirrhosis, Asian males over forty, Asian females over fifty, African patients over twenty, and patients with a family history of HCC. Surveillance with abdominal ultrasound every six months is the standard, with or without alpha-fetoprotein measurement. HBV suppression with NUC therapy reduces but does not eliminate HCC risk, and the clinician who achieves undetectable viral load and normalizes ALT but fails to implement HCC surveillance has addressed only part of the clinical picture. This is the aspect of HBV management that is most frequently missed in primary care settings.
Limitations and the Functional Cure Frontier
Current antiviral therapy for HBV is suppressive, not curative — HBsAg loss (functional cure) occurs in fewer than five percent of patients on indefinite NUC therapy. The functional cure pipeline includes siRNA agents (bepirovirsen), capsid assembly modulators, and therapeutic vaccines, but none have yet demonstrated the reliability needed for widespread clinical adoption. NUC discontinuation is an intriguing strategy to stimulate immune-mediated HBsAg clearance, but the hepatitis flares that accompany it carry real risk, particularly in patients with underlying fibrosis. Until functional cure therapies mature, the management framework remains: identify patients who need treatment, initiate tenofovir or entecavir, monitor adherence and viral response, maintain HCC surveillance, and counsel patients that this is a long-term commitment to disease control rather than a time-limited course of therapy.
References
- Comparative efficacy of tenofovir and entecavir on hepatocellular carcinoma risk reduction in chronic hepatitis B patients PubMed 31021386
- Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with a higher risk of HBsAg loss: results of a follow-up study (STOP-NUC) PubMed 37062574
- Bepirovirsen, an RNA Interference Agent, for Chronic Hepatitis B Infection PubMed 37902953
Frequently Asked Questions
Is tenofovir or entecavir better for preventing HCC in hepatitis B?
What are the renal advantages of TAF over TDF for hepatitis B?
When can nucleos(t)ide analog therapy be safely discontinued in HBV?
What is the rate of HBsAg loss with nucleos(t)ide analogs alone?
Who should receive HBV antiviral therapy per 2024 EASL guidelines?
What HBsAg decline rate predicts eventual functional cure?
Explore This Topic in Ailva
Ailva is a free clinical intelligence platform for NPI-verified US physicians. Get evidence-based answers with verified citations from 16M+ indexed papers — plus free CME credits.
Founder of Ailva.ai | Former Director of Research and Author of 200+ Medically Reviewed Articles | Editor-in-Chief of EudaLife Magazine